Exelixis | EXEL - Stock

Stock Price
50.13
Daily Change
-0.97 -1.90%
Monthly
12.96%
Yearly
10.42%
Q2 Forecast
49.12

Exelixis reported $26.6M in Stock for its fiscal quarter ending in March of 2026.





Stock Change Date
Acadia Pharmaceuticals USD 31.57M 3.1M Mar/2026
Agios Pharmaceuticals USD 35.09M 2.17M Mar/2026
Akebia Therapeutics USD 13M 2.61M Mar/2026
Amgen USD 6.19B 39M Mar/2026
AstraZeneca USD 6.57B 13M Mar/2026
Bayer EUR 12.34B 3M Dec/2025
BioMarin Pharmaceutical USD 1.27B 25.66M Mar/2026
Bristol-Myers Squibb USD 2.76B 66M Mar/2026
Eisai JPY 236.46B 9.14B Sep/2025
Eli Lilly USD 14.53B 785M Mar/2026
Esperion Therapeutics USD 104.21M 915K Mar/2026
Exelixis USD 26.6M 4.92M Mar/2026
Genmab DKK 13M 1000K Jun/2025
Glaxosmithkline GBP 6.12B 46M Sep/2025
Incyte USD 115.62M 14.56M Mar/2026
Ionis Pharmaceuticals USD 5.56M 4.49M Mar/2026
MacroGenics USD 9.5M 1.59M Mar/2026
Merck USD 6.48B 179M Mar/2026
Moderna USD 146M 7M Mar/2026
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Neurocrine Biosciences USD 64.5M 4.5M Mar/2026
Novartis USD 6.29B 17M Mar/2026
Pfizer USD 10.67B 13M Mar/2026
Puma Biotechnology USD 9.48M 885K Sep/2025
Sanofi EUR 22.69B 1.81B Dec/2025
Takeda JPY 1.41T 107.71B Dec/2025
Ultragenyx Pharmaceutical USD 55M 3M Mar/2026